
Join to View Full Profile
UT Physicians Neurocognitive Disorders1941 E Rd, Ste 4358Houston, TX 77054
Phone+1 713-486-0500
Fax+1 713-383-1435
Dr. Schulz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul Schulz is a neurologist at UTHealth Houston in Houston, TX. He received his medical degree from Boston University School of Medicine, did a residency in neurology and a fellowship in Cellular Neurophysiology, both at Baylor College of Medicine. He has been in practice for 37 years. He sees patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD), does medication clinical trials with that group, investigates mechanisms underlying MCI/AD, and investigates new diagnostic tools for them.
Education & Training
Baylor College of MedicineResidency, Neurology, 1985 - 1988
Boston VA Healthcare System (Brockton-West Roxbury)Internship, Internal Medicine, 1984 - 1985
Boston UniversityB.A., Medical Sciences and Psychology, Magna Cum Laude, 1977 - 1984
Boston University School of MedicineClass of 1984
Certifications & Licensure
TX State Medical License 1988 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- “Dean’s Excellence in Teaching Award” UTHealth, 2022
- "Dean's Teaching Excellence Award" UTHealth, 2012
- "Doctor's Choice" Health and Fitness Magazine, 2009
- Join now to see all
Clinical Trials
- Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Start of enrollment: 2015 Jul 01
- A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). Start of enrollment: 2016 Mar 22
- A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Cortical thickness and low-grade inflammation moderate the association between depressive symptoms and cognitive function in early widowhood: A preliminary study.E Lydia Wu-Chung, Kristen M Kennedy, Luis D Medina, Paul E Schulz, Frederick L Oswald
Brain, Behavior, and Immunity. 2025-10-01 - Generation of human induced pluripotent stem cell line from a familial Alzheimer's disease patient carrying missense mutations in PSEN1 and MAPT genes.Ashaq H Najar, Sofia E Sepulveda, Camila Gherardelli, Fatemeh Elahian, Amber Fontenot-Roberts
Stem Cell Research. 2025-09-01 - Risk of major depression in partners of people with Alzheimer's disease: a national cohort study.Casey Crump, Jingkai Wei, Barbara G Vickrey, Alexis C Edwards, Paul E Schulz
Age and Ageing. 2025-08-29
Journal Articles
- Delirious Mania in Bipolar DisorderKimm, TS, Okusaga OO, and Schulz PE, Prim Care Companion CNS Disord, 1/2/2017
- Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With SclerosisCykowski MD, Powell SZ, Schulz PE, Takei H, Rivera AL, Jackson RE, Roman G, Jicha GA, and Nelson PT, Arch Pathol Lab Med, 1/1/2017
- NeuropsychiatryArora G, Schulz PE, Neurology Secrets, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Deep Brain Stimulation of the Medial Forebrain Bundle: Significant Responses in Treatment Resistant Depression.Fenoy AJ, Schulz P, Selvaraj S, Burrows, Zunta-Soares G, Quevedo J, Soares JC, North American Neuromodulation Society (NANS) 21st Annual Meeting, Las Vegas, NV, 1/11/2018
- Evidence for neuroinflammation in semantic dementia.Pascual MB, Roman GC, Yu M, Pal N, Rockers ED, Fregonara Z, Funk Q, Schulz PE, and Masdeu J, Human Amyloid Imaging Conference, 1/1/2018
- Nonfluent variant of primary progressive aphasia: Tau deposition in the language network.Pascual B, Zanotti-Fregonara P, Funk Q, Rockers E, Pal N, Yu M, Spann B, Schulz P, Masdeu J, American Academy of Neurology (AAN) Meeting, 1/1/2017
- Join now to see all
Lectures
- "Lewy Body Dementia"Austin, TX - 1/25/2017
- "Update on Neuroimaging and Therapeutic Trials in Alzheimer's Disease"Austin, TX - 1/25/2017
- "Recent Advances in Diagnosing and Treating AD"University of Texas Medical Branch, Galveston, TX - 1/22/2017
- Join now to see all
Other
- "Pimavanserin for Parkinson's Disease Psychosis."Schulz PE, Webinar with Fort Worth MDs
1/31/2017 - Commenting on the radio on "It's impossible to ignore this anymore': CTE study details devastating toll on football players."Schulz PE, News Talk 710 KURV
TX - 1/26/2017 - "Alzheimer's Day."Schulz PE, KRUV Radio
1/23/2017 - Join now to see all
Press Mentions
Breakthrough Study Links Vaccines to Reduced Alzheimer’s RiskJuly 5th, 2025
Getting This Shot Lowered Seniors’ Dementia Risk by 20%April 2nd, 2025
Groundbreaking Stem Cell Therapy Trial for Alzheimer's Disease Underway at UTHealth HoustonMarch 13th, 2025- Join now to see all
Grant Support
- Mechanisms underlying COVID-19 induced Neurocognitive DysfunctionUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2023–2028
- Pilot Study--Amyloid Mediated ToxicityNational Institute On Aging1995–2000
External Links
- All PubMed Publicationshttps://www.ncbi.nlm.nih.gov/myncbi/1d3Rdqa1xETkm7/bibliography/public/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









